Coding · November 13, 2026
Basal Cell Carcinoma ICD-10 Codes (C44.x): How to Code BCC for Dermatology Billing
Basal cell carcinoma ICD 10 codes sit in category C44, with a fifth character of 1 for basal cell and site characters such as C44.311 for the nose. This guide covers BCC codes by site, how they differ from SCC and melanoma, holding charges until pathology, linking C44 to Mohs, excision and repair lines, and when Z85.828 replaces the active code.
This article is part of the dermatology billing blog, where we cover coding, denials and payer policy as they change.
More articles
- Skin Cancer Screening CPT Code: How to Bill a Full Body Skin Exam With Z12.83 (2027 Guide)
- 2027 Medicare Physician Fee Schedule for Dermatology: What Changes on January 1, 2027
- Dermatology Consultation CPT Code Guide: 99242-99245, Medicare Rules and What to Bill Instead
- Skin Tag Removal CPT Codes 11200 and 11201: How to Code and Count (2026)
- LCD vs NCD in Medical Billing: What Dermatology Practices Need to Know in 2026
- GZ Modifier: Complete Guide to Advance Beneficiary Notice Denials and Compliance
In this guide
- How Is a Basal Cell Carcinoma ICD 10 Code Built?
- Most Used Basal Cell Carcinoma ICD 10 Codes by Site
- How Do BCC Codes Differ From SCC, Melanoma, In Situ and Uncertain Behavior Codes?
- Should You Hold Charges Until the Pathology Report Is Back?
- How Does the C44 Code Link to Mohs, Excision, Destruction and Repair?
- Worked Example: From BCC Biopsy to Mohs With the Diagnosis on Each Line
- History of Basal Cell Carcinoma: Z85.828 vs Active C44 Codes
- Original Medicare, Medicare Advantage and Commercial Plans: What Differs for BCC Claims
- Which ICD-10-CM Code Set Applies to Your BCC Claims?
- Common BCC Coding Mistakes and the Denials They Cause
- Get Your BCC Claims Checked Against the Pathology Report
- Sources
- Frequently Asked Questions
- Want this checked against your own claims?

Quick answer: Basal cell carcinoma ICD 10 codes sit in category C44. Each code combines a body site, a fifth character of 1 that marks basal cell, and laterality where the site has it, such as C44.311 for the nose and C44.41 for the scalp and neck. Report C44.91 only when no site is documented, and code from the final pathology report.
A basal cell carcinoma (BCC) claim can fail in one of three places. The diagnosis names no site, the site on the pathology report does not match the operative note, or the charge left the building before the pathology report came back. Any of the three gives a payer a reason to question a Mohs or excision line that was routine on the clinical side.
The fiscal year (FY) 2027 diagnosis code set has applied to encounters since October 1, 2026, according to the CMS ICD-10 page. This guide is for dermatology coders, billers and practice managers, and it supports our dermatology coding services. It follows one lesion from biopsy to Mohs, with the diagnosis on every claim line.
How Is a Basal Cell Carcinoma ICD 10 Code Built?
A BCC code starts with C44, adds a body-site character, then a fifth character of 1 for basal cell, then laterality or site-part characters where the tabular list requires them.
C44 is the ICD-10-CM category for other and unspecified malignant neoplasms of skin. ICD-10-CM is the Clinical Modification of the International Classification of Diseases, 10th Revision, the diagnosis code set that every HIPAA-covered payer uses. Squamous cell carcinoma (SCC) shares the category and takes a fifth character of 2, so one wrong digit turns a BCC claim into an SCC claim.
Reading Two Codes Character by Character
Two examples show how the characters stack up.
- C44.311: C44 is the category, 3 is the face group, 1 marks basal cell, and the final 1 is the nose.
- C44.1121: C44 is the category, 1 is the eyelid group, 1 marks basal cell, 2 is the right side, and the final 1 is the upper eyelid.
C44.311 · Nose
- Category
- C44
- Face group
- 3
- Basal cell
- 1
- Nose
- 1
A 2 in the basal cell position reads as SCC.
C44.1121 · Right upper eyelid
- Category
- C44
- Eyelid group
- 1
- Basal cell
- 1
- Right side
- 2
- Upper eyelid
- 1
A coder who knows this pattern can catch a bad code in seconds. A charge for a BCC that carries a 2 in the fifth position reads as SCC.
Why Unspecified-Site Codes Cause Trouble
C44.91 reports a BCC with no site, and it belongs on a claim only when the record truly has no site. Excision, destruction, Mohs and repair codes are all chosen by anatomic location, so a diagnosis with no site cannot be checked against the procedure line.
Chapter III of the Medicare NCCI Policy Manual tells providers to report the procedure code to the greatest specificity possible. Hold the diagnosis to the same standard. When the operative note names the nose and the claim says C44.91, the fix is a short provider query, not a default code.
Most Used Basal Cell Carcinoma ICD 10 Codes by Site
The most used BCC codes run from C44.01 for the lip to C44.91 for an unspecified site, with C44.311 for the nose and C44.41 for the scalp and neck among the most specific.
BCC code families by skin site, FY 2027 ICD-10-CM. Confirm each code in the CMS 2027 code descriptions before loading a picklist.
| Body site | BCC code | Laterality or part | Note |
|---|---|---|---|
| Lip | C44.01 | None | Skin of the lip |
| Eyelid, including canthus | C44.111, C44.1121, C44.1122, C44.1191, C44.1192 | Unspecified; right upper and lower; left upper and lower | Pick side and lid from the note |
| Ear and external auricular canal | C44.211, C44.212, C44.219 | Unspecified, right, left | Left side ends in 9 |
| Nose | C44.311 | None | Own code within the face group |
| Other parts of face | C44.319 | None | Face sites outside the nose, lip, ear and eyelid |
| Scalp and neck | C44.41 | None | One code covers both |
| Trunk | C44.519 | Other part of trunk | Breast skin and anal skin take a different sixth character |
| Upper limb, including shoulder | C44.61 plus a sixth character | Unspecified, right or left | Choose the side from the note |
| Lower limb, including hip | C44.71 plus a sixth character | Unspecified, right or left | Choose the side from the note |
| Overlapping sites | C44.81 | None | One lesion crossing two site groups |
| Unspecified site | C44.91 | None | Use only when no site is documented |
Build the charge-entry picklist from the site column, not from a free-text search. A coder who types "basal cell" into a search box can land on a code for the wrong eyelid or the wrong limb, and the screen will not complain.
How Do BCC Codes Differ From SCC, Melanoma, In Situ and Uncertain Behavior Codes?
BCC and SCC share category C44 and differ by the fifth character, melanoma is C43, carcinoma in situ of skin is D04, and neoplasms of uncertain or unspecified behavior use D48.5 and D49.2.
The pathology wording decides the category. A coder does not pick between C44, D04 and D48.5 from the clinical impression.
Skin diagnosis families a dermatology coder meets after a biopsy.
| Pathology result | Code family | Note |
|---|---|---|
| Basal cell carcinoma | C44.x1 | Fifth character 1; C44.311 for the nose |
| Squamous cell carcinoma | C44.x2 | Same site digits as BCC, fifth character 2 |
| Melanoma | C43 | Separate category, never C44 |
| Merkel cell carcinoma | C4A | Separate category |
| Melanoma in situ | D03 | In situ melanoma stays out of C43 |
| Carcinoma in situ of skin | D04 | Not C44 |
| Benign neoplasm of skin, nevus | D22, D23 | Pairs with benign procedure codes |
| Uncertain behavior | D48.5 | The report says behavior cannot be determined |
| Unspecified behavior | D49.2 | No behavior stated |
A D48.5 or D49.2 code should be temporary. If the final report names a BCC, replace the uncertain code before the claim goes out. If the report gives an addendum days later, the diagnosis on a claim already sent needs a correction.
Should You Hold Charges Until the Pathology Report Is Back?
Yes. Hold the biopsy charge and any excision charge until the final pathology report is in the chart, because the diagnosis code and the benign or malignant procedure family both depend on that result.

The outpatient section of the FY 2027 ICD-10-CM Official Guidelines has its own rule for uncertain diagnoses. In an outpatient setting, a "suspected" or "probable" diagnosis is not reported as confirmed. Until pathology confirms a BCC, only the documented findings are coded.
The same logic splits excision codes. The Medicare NCCI Policy Manual lists excision of benign lesions under 11400 to 11471 and excision of malignant lesions under 11600 to 11646. The pathology result decides which family fits the specimen.
Here is a hold workflow a front-end team can follow:
- Biopsy the lesion and record the exact site, side and lesion count in the procedure note.
- Place the charge on hold with a reason of "pathology pending".
- Match the incoming pathology report to the chart and the specimen.
- Ask the provider to document the result in the visit note, so the diagnosis comes from the provider's record and not from the lab report alone.
- Assign the C44 code from the pathology wording, then release the charge.
Suppose the biopsy charge goes out on the day of the procedure with a lesion code, and the report then reads BCC. That forces a corrected claim and a second review of every later line for that lesion. Our guide to holding excision charges until pathology covers the hold rules in depth. For the lab side, see our dermatopathology billing guide.
How Does the C44 Code Link to Mohs, Excision, Destruction and Repair?
The C44 code goes on every line that treats the BCC, and it must match the site in the operative note. Chapter III of the Medicare NCCI Policy Manual, revised January 1, 2026, sets the rules for combining those lines.

Procedure families that take a C44 diagnosis, with the Medicare NCCI point for each (Chapter III, revision date January 1, 2026).
| Procedure family | CPT code numbers | Diagnosis to link | NCCI point |
|---|---|---|---|
| Skin biopsy | 11102-11107 | Path-confirmed C44 code | Included in removal of the same lesion at the same encounter |
| Excision, benign lesions | 11400-11471 | A benign code, not C44 | Repairs of 0.5 cm or less excisions are not separate |
| Excision, malignant lesions | 11600-11646 | C44 code for the site | Intermediate and complex repairs may be reported |
| Destruction, benign or premalignant | 17000, 17004 | A benign or premalignant code, not C44 | Paired with biopsy codes by NCCI edits |
| Destruction, malignant | 17260-17286 | C44 code for the site | One removal code per lesion |
| Mohs surgery | 17311-17315 | C44 code for the site | Includes biopsy, excision and pathology services |
| Repair, flaps and grafts | 12001-13160, 14000-14350 | Same C44 code as the removal line | Simple repair is part of lesion removal |
Mohs Surgery
NCCI describes Mohs micrographic surgery as the removal of a complex or ill-defined cutaneous malignancy, with one physician doing both the surgery and the pathologic examination. The Mohs codes include skin biopsy and excision services and surgical pathology, so those codes are not reported in addition to the Mohs codes.
A diagnostic biopsy before Mohs is the exception. NCCI allows the biopsy and frozen section code 88331 to be reported with modifier 59, XS or XU, or with modifier 58 for a planned, staged procedure. Repairs, grafts and flaps are separately reportable with Mohs. Our Mohs surgery billing guide shows how stages and blocks are counted.
NCCI also allows only one unit of 88342 per specimen for an initial antibody stain, with 88341 added for each different antibody stain. The unit is the specimen, not each block.
Malignant Excision
NCCI allows only one removal code per lesion, and removal includes the biopsy of the same lesion at the same encounter. Biopsy codes 11102 to 11107 may be separate only when the biopsy was on a different lesion from the removal.
Closure rules decide how many lines the claim carries. Simple repair codes 12001 to 12021 are part of lesion removal. Intermediate or complex repairs, adjacent tissue transfer and grafts may be reported when medically reasonable and necessary. Adjacent tissue transfer includes the excision, so 11600 to 11646 are not reported separately with it for the same lesion.
Destruction
BCC destruction belongs in the malignant destruction range, 17260 to 17286, and not in 17000 or 17004, which NCCI describes as destruction of benign or premalignant lesions. Linking C44 to 17000 or 17004 sends a mismatch the payer can see. Our lesion destruction coding guide covers counts and units.
NCCI also pairs biopsy codes 11102, 11104 and 11106 with 17000 and 17004. Modifier 59, XE or XS is appropriate only when the two services were on separate lesions or at separate encounters.
Repair, Flaps and Grafts
Repair lines carry the same C44 code as the excision or Mohs line they close. For a Mohs defect, NCCI allows simple, intermediate and complex repairs to be reported with 17311 to 17315. For an excision of a benign lesion of 0.5 cm or less, NCCI includes the repair in the excision.
Worked Example: From BCC Biopsy to Mohs With the Diagnosis on Each Line
A hypothetical Original Medicare patient has a nose lesion biopsied on October 5, 2026. Pathology returns on October 8, and Mohs follows on October 26, which is 21 days after the biopsy. Every date falls in the FY 2027 code set.
The codes below illustrate the pattern. A real coder selects them from the operative note and the pathology report, and nothing in this example is a clinical recommendation.
- October 5, 2026: the provider biopsies the lesion and documents the nose as the site. The practice places the charge on hold.
- October 8, 2026: the pathology report returns with a BCC diagnosis, 3 days after the biopsy. The provider documents the result in the chart.
- Release the biopsy charge: the coder assigns C44.311 and releases the biopsy line with that diagnosis.
- October 26, 2026: the Mohs surgeon removes the BCC in 2 stages and closes the defect. Every line carries C44.311.
- Check the claim: the coder confirms the code set, the site and the side match across both dates before release.
- Step 1
Oct 5, 2026
Biopsy of nose lesion; charge on hold
- Step 2
Oct 8, 2026
Pathology returns BCC
- Step 3
Release
Biopsy line released with C44.311
- Step 4
Oct 26, 2026
Mohs, 2 stages, repair; all lines C44.311
Claim lines for the example, with the diagnosis pointer on each line.
| Date of service | Line | Code | Diagnosis on the line | Note |
|---|---|---|---|---|
| October 5, 2026 | 1 | 11102 | C44.311 | Released after the October 8, 2026 report |
| October 5, 2026 | 2 | 88305 | C44.311 | Billed by whoever interprets the slides; your claim only with an in-house lab |
| October 26, 2026 | 1 | 17311 | C44.311 | First Mohs stage |
| October 26, 2026 | 2 | 17312 | C44.311 | Second Mohs stage |
| October 26, 2026 | 3 | 12051 | C44.311 | Intermediate repair, separately reportable with Mohs |
The biopsy and the Mohs surgery fall on different dates, so no modifier 59, XS, XU or 58 is needed to separate them. NCCI procedure-to-procedure (PTP) edits are based on services by the same physician on the same date of service. Had the biopsy and Mohs happened the same day, the modifiers in the Mohs section above would apply.
Consider what goes wrong. If the biopsy line had gone out on October 5 with C44.91, and the Mohs claim carried C44.311, the same lesion would carry two different diagnoses on two claims. An office visit on the biopsy date takes modifier 25 only when it is separately identifiable, and NCCI says the visit and the minor procedure do not need different diagnoses. Our skin biopsy coding guide explains when that visit is billable.
*Diagnosis codes not matching your Mohs and excision claims?* The request form for a [free claims audit](https://dermbillingusa.com/free-dermatology-claims-audit) is near the end of this guide, under "Get Your BCC Claims Checked Against the Pathology Report".
History of Basal Cell Carcinoma: Z85.828 vs Active C44 Codes
Z85.828, personal history of other malignant neoplasm of skin, replaces the C44 code only after the BCC has been excised or eradicated and no evidence of it remains at that site. While treatment is still directed at the site, the C44 code stays.

The FY 2026 ICD-10-CM Official Guidelines state both halves of the rule in section I.C.2. A Z85 code is used when a primary malignancy was excised or eradicated with no evidence at that site. When further treatment, such as another surgery or radiation, is directed to the site, the primary malignancy code is used until treatment is complete. The FY 2027 guidelines linked above apply to encounters from October 1, 2026, so re-read Section I.C.2 there.
Which code fits which BCC encounter.
| Situation | Code to report | Reason |
|---|---|---|
| BCC confirmed, treatment not yet done | C44 code for the site | The cancer is active |
| Mohs stage or further surgery directed at the site | C44 code for the site | Treatment is still under way |
| Follow-up visit after completed treatment, no evidence at the site | Z08 with Z85.828 | History of skin cancer; follow-up after treatment |
| New BCC at a different site | New C44 code for the new site | A separate primary lesion |
| Screening skin check with no complaint | Z12.83 first | See our skin cancer screening coding guide |
Z08 is the encounter for a follow-up exam after completed treatment for a malignant neoplasm. Z85.828 covers other malignant neoplasms of skin, such as BCC, and Z85.820 is the melanoma history code.
What goes wrong: coders leave the C44 code on every follow-up visit because it is already on the problem list. If the provider documents that the site is clear, the claim should carry the history code. The reverse error also happens, when Z85.828 sits on a claim for a lesion that has just been re-biopsied and read as BCC.
Original Medicare, Medicare Advantage and Commercial Plans: What Differs for BCC Claims
The ICD-10-CM code is the same for every payer, but the edits, diagnosis lists and policy documents differ by payer type, so each claim follows its own payer's rules.
CMS states that ICD-10 applies to all parties covered by the Health Insurance Portability and Accountability Act (HIPAA), not only providers who bill Medicare or Medicaid. A C44.311 on a commercial claim means the same thing as on a Medicare claim. What changes is who enforces which edit.
Who sets the rules for BCC claims by payer type.
| Payer type | Who sets the rules | What to check before billing |
|---|---|---|
| Original Medicare (Part B) | CMS, through the NCCI Policy Manual for Medicare effective January 1, 2026 | NCCI Chapter III edits; your Medicare Administrative Contractor (MAC) for claim-specific questions and appeals |
| Medicare Advantage | The plan, through its provider manual and coding policies | The plan's Mohs and excision policy and any authorization rule |
| Commercial | Each payer's own policy | The payer's Mohs and excision policy, modifier rules and diagnosis lists |
| Medicaid | The state program; CMS publishes a separate Medicaid NCCI manual | The state's billing manual and the Medicaid NCCI Chapter III with a January 1, 2026 revision date |
The CMS NCCI for Medicare page says claim-specific inquiries and appeals go to the MAC, and that the NCCI program cannot answer questions about other payors or about local coverage determinations. A local coverage determination (LCD) is a MAC's own coverage rule, and it can attach diagnosis requirements to Mohs. This guide uses CMS national sources only, so check your MAC's LCD and billing articles before you finalize a Mohs diagnosis list.
Which ICD-10-CM Code Set Applies to Your BCC Claims?
Encounters from October 1, 2026 through September 30, 2027 use the FY 2027 ICD-10-CM code set. The date of service picks the code set, not the date the claim is sent.
ICD-10-CM code set by encounter date, per the CMS ICD-10 page.
| Encounter dates | Code set | Files to use |
|---|---|---|
| October 1, 2025 to March 31, 2026 | FY 2026 October release | 2026 files |
| April 1, 2026 to September 30, 2026 | FY 2026 April update | April 1, 2026 files |
| October 1, 2026 to September 30, 2027 | FY 2027 | 2027 files |
CMS publishes a 2027 addendum that lists added, deleted and revised codes, plus a 2027 conversion table. Run your BCC picklist against the addendum before it goes live, and check older files in the CMS ICD-10 files archive for claims with earlier dates of service. The documentation trade group ACDIS reported that the FY 2027 guidelines revised several areas, including cancer treatment and Z codes, which are the two areas this guide leans on. Our dermatology coding updates page tracks the changes that touch dermatology.
Common BCC Coding Mistakes and the Denials They Cause
BCC claims run into trouble where the diagnosis disagrees with the procedure line or with the pathology report. Each mistake below has a fix a coder can apply before release.

BCC coding mistakes, the denial they can trigger and the fix.
| Mistake | Why it fails | Possible denial or edit | Fix |
|---|---|---|---|
| C44.91 on a Mohs or excision line | No site to match the procedure | Claim adjustment reason code (CARC) 11, diagnosis inconsistent with the procedure | Query the provider for the site in the operative note |
| SCC fifth character on a BCC | Histology and code disagree with the report | Record request; mismatch with the pathology claim | Code from the report wording, not the clinical impression |
| "Suspected BCC" coded as C44 before pathology | Outpatient rules do not report uncertain diagnoses as confirmed | Corrected claim later | Hold the charge until the report returns |
| C44 linked to 17000 or 17004 | Those codes describe benign or premalignant destruction | CARC 11 or CARC 50, not medically necessary | Use the malignant destruction range for a BCC |
| Biopsy billed with excision of the same lesion | Removal includes the biopsy of that lesion | CARC 97, benefit included in another service | Drop the biopsy line; keep it only for a different lesion |
| Biopsy and Mohs on one date with no modifier | NCCI pairs them; the modifier signals a staged diagnostic biopsy | NCCI edit denial | Add modifier 59, XS, XU or 58 as NCCI allows |
| Z85.828 on an active site, or C44 on a cleared site | The status of the cancer decides the code | Medical necessity review | Apply the Z85 rule from the guidelines |
| Wrong side or lid on an eyelid or ear code | Laterality is part of the code | Record request or audit finding | Check the side against the operative note |
Match each denial to its remittance code in our dermatology denial codes index. Each payer words its denials differently, so treat the third column as what can happen, not what always happens.
Insider tip: pull a list of every claim that carried C44.91 in the last quarter and compare it with the operative notes. Each hit is a coding or documentation gap you can close at the source.
Get Your BCC Claims Checked Against the Pathology Report
Diagnosis codes not matching your Mohs and excision claims? DermBilling USA codes dermatology claims for dermatology, dermatopathology and Mohs practices. A free claims audit reviews a de-identified sample of your claims and returns a line-item report on coding gaps and denial causes.
Signs your BCC claims need a second look:
- Biopsy charges leave the practice before pathology returns.
- Mohs and excision lines carry C44.91 or a site that differs from the operative note.
- Repair lines deny while the excision lines pay.
- Follow-up visits carry active C44 codes after treatment is complete.
Never send patient names, dates of birth or other protected health information through the request form.
Sources
- ICD-10, CMS Medicare Coding & Billing, Centers for Medicare & Medicaid Services
- FY 2027 ICD-10-CM Official Guidelines for Coding and Reporting, CMS
- FY 2026 ICD-10-CM Official Guidelines for Coding and Reporting, CMS
- Medicare NCCI Policy Manual, Chapter III, Surgery: Integumentary System, CMS, revision date January 1, 2026
- Medicare NCCI Policy Manual, CMS, effective January 1, 2026
- National Correct Coding Initiative (NCCI) Edits for Medicare, CMS
- Medicaid NCCI Policy Manual, Chapter III, Surgery: Integumentary System, CMS, revision date January 1, 2026
- ICD-10 Files and News Archive, CMS
- CMS Releases FY 2027 ICD-10-CM Coding Guidelines, ACDIS
This guide is a billing reference, not legal or coding advice for a specific claim. Check your MAC and each payer's current policy before billing.
Primary sources
Coding and coverage rules change. Verify against the source before you bill.
- CMS Physician Fee Schedule lookupNational and locality payment amounts for dermatology CPT codes
- CMS Medicare Coverage Database (LCDs & articles)MAC-jurisdiction local coverage determinations and billing articles
- CMS National Correct Coding Initiative (NCCI) editsProcedure-to-procedure edits and modifier indicators
- CMS Medicare Claims Processing ManualAuthoritative claim submission and payment rules
- AMA CPT coding resourcesOfficial CPT code set guidance and annual changes
- AAPC certification directoryVerification path for CPC, CPMA, CPB and CHC credentials
Where this sits in our reference library
The evergreen pages behind this article, kept current as payer policy moves.
Frequently Asked Questions
No single code covers it. BCC codes begin with C44, carry a fifth character of 1, and add the site, such as C44.311 for the nose or C44.41 for the scalp and neck. C44.91 is the code for a BCC with no documented site.
C44.311. The fifth character 1 marks basal cell, and the final 1 places the lesion on the nose. Confirm the code in the CMS 2027 tabular files before loading it into a picklist.
Yes, but only when the record gives no site. When the operative note or pathology requisition names a site, a site-specific C44 code is the right choice, and the claim should be held while the provider is queried.
No. A suspected BCC is not reported as confirmed in the outpatient setting. Hold the charge until the final report is in the chart, then code the result.
Z85.828 reports a personal history of other malignant neoplasm of skin. Use it when the BCC was excised or eradicated and no evidence remains at the site, and add Z08 for a follow-up visit after completed treatment.
Yes. Each line that treats or closes the same BCC points to the same site-specific C44 code. A line for a different lesion points to the code for that lesion's own site.
No. The ICD-10-CM code is the same for every HIPAA-covered payer. The plan's own edits, diagnosis lists and authorization rules are what differ, so check each payer's Mohs and excision policy.
About the Author
CEO of DermBillingUSA
Touseef Riaz is CEO of DermBillingUSA and writes about dermatology practice revenue cycle management, billing operations, and business performance.
LinkedIn
